Teprotumumab Gives Lasting Relief from Thyroid Eye Disease

Thyroid Disorder News

Teprotumumab Gives Lasting Relief from Thyroid Eye Disease
Thyroid DiseaseThyroid DysfunctionThyroid Associated Ophthalmopathy
  • 📰 Medscape
  • ⏱ Reading Time:
  • 44 sec. here
  • 24 min. at publisher
  • 📊 Quality Score:
  • News: 98%
  • Publisher: 55%

Nearly 2 years after their final teprotumumab transfusion, 82% of patients didn't need further treatment.

"Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated," said George Kahaly, MD, PhD, professor of medicine and endocrinology at Johannes Gutenberg University Medical Center in Mainz, Germany. For their analysis, they analyzed pooled clinical trial data beyond the 24-week treatment period for patients who received the full course in the phase 2/3 studies.

Similar to week 24 results, 51 weeks after therapy most participants maintained response to teprotumumab for the composite outcome ; clinical activity score ; diplopia ; proptosis ; and overall response . Overall, during the 99 weeks of follow-up, the longest to date, 82% of 106 reporting patients did not need additional thyroid eye disease treatment post-teprotumumab therapy .

Adverse effects were consistent with the known safety profile of teprotumumab. Four cases of hyperglycemia were newly reported during the follow-up, three of which were resolved and one was ongoing, as the patient discontinued the study due to a flare. Three cases of"As physicians consider treatment approaches for their thyroid eye disease patients, they now have longer-term data to support the use of teprotumumab in appropriate patients," Kahaly said.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

Thyroid Disease Thyroid Dysfunction Thyroid Associated Ophthalmopathy Thyroid Eye Disease Thyroid Ophthalmopathy Endocrine Society Eye Thyroid Transfusion Diplopia Double Vision Hearing Impairment Patient Safety Adverse Effects Side Effects Autoimmune Disease Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial Double-Blind Study Double-Blind Studies

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Teprotumumab Treats Thyroid Eye Disease Across AgeTeprotumumab Treats Thyroid Eye Disease Across AgeFindings refute those of a prior study suggesting a better response in older vs younger patients.
Read more »

Debt relief ripoff: Woman hires relief firm, ends up deeper in debtDebt relief ripoff: Woman hires relief firm, ends up deeper in debtKnow the risks of hiring a company to help with bills.
Read more »

Operation BBQ Relief gives out over 1,800 meals to North Texans affected by stormsOperation BBQ Relief gives out over 1,800 meals to North Texans affected by stormsThe man's body was recovered Saturday evening after witnesses told police he jumped off a boat and didn't resurface.
Read more »

11 Long-Lasting Celebrity Couples Who Don’t Live Together (Or Waited Years To Move In)11 Long-Lasting Celebrity Couples Who Don’t Live Together (Or Waited Years To Move In)See which couples held off on moving in together, and why!
Read more »

Gaza truce talks make reported progress but Israel skeptical of lasting peace with HamasGaza truce talks make reported progress but Israel skeptical of lasting peace with HamasA Hamas delegation was in Cairo on Saturday as Egyptian state media reported 'noticeable progress' in cease-fire talks for Gaza.
Read more »

These 5 NYC tourist sites prove lasting popularity of 'Friends' TV sitcomThese 5 NYC tourist sites prove lasting popularity of 'Friends' TV sitcomThe last episode of 'Friends' aired on May 6, 2004, yet the appeal of the show is evident 20 years later in the popularity of these five New York City tourist attractions.
Read more »



Render Time: 2025-02-14 20:42:13